TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06393738: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Sponsor: Arvinas Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 329 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$6,157,536

Rescue Site Savings

+$4,052,664

Unlock Full NCT06393738 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06393738 Rescue Dossier →